Nature Clinical Practice. Cardiovascular Medicine最新文献_第7页

Embryonic stem cells prevent developmental cardiac defects in mice. 胚胎干细胞可预防小鼠发育性心脏缺陷。

Nature Clinical Practice. Cardiovascular Medicine Pub Date : 2006-03-01 DOI: 10.1038/ncpcardio0402

Diego Fraidenraich, Robert Benezra

引用次数: 21

Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. 间充质系前体细胞诱导缺血心肌血管网络的形成。

Nature Clinical Practice. Cardiovascular Medicine Pub Date : 2006-03-01 DOI: 10.1038/ncpcardio0404

Timothy P Martens, Fiona See, Michael D Schuster, Hugo P Sondermeijer, Marco M Hefti, Andrew Zannettino, Stan Gronthos, Tetsunori Seki, Silviu Itescu

引用次数: 103

Surgical and catheter delivery of autologous myoblasts in patients with congestive heart failure. 充血性心力衰竭患者自体成肌细胞的手术和导管输送。

Nature Clinical Practice. Cardiovascular Medicine Pub Date : 2006-03-01 DOI: 10.1038/ncpcardio0399

Shaun R Opie, Nabil Dib

{"title":"Surgical and catheter delivery of autologous myoblasts in patients with congestive heart failure.","authors":"Shaun R Opie, Nabil Dib","doi":"10.1038/ncpcardio0399","DOIUrl":"https://doi.org/10.1038/ncpcardio0399","url":null,"abstract":"Autologous skeletal myoblast (ASM) transplantation is being explored as a possible therapy for patients who have suffered a myocardial infarction. Our initial experience with direct injection during coronary artery bypass grafting demonstrated that this method of delivery was both feasible and safe. In addition, proof of concept of the engraftment and survival of ASMs was shown. However, since many patients who have survived a myocardial infarction are not candidates for surgery, a less invasive delivery method is preferred. We implemented a series of translational research steps to bring catheter-based technology to a clinical application. This included assessing the biocompatibility of the ASM and a novel needle injection catheter using a 3-dimensional endoventricular navigation system, the bioretention and biodistribution of ASMs in a porcine model of myocardial infarction, and the safety and efficacy of ASM transplantation for cardiac function in the porcine model. After catheter functionality had been demonstrated, electromechanical mapping was used to assess the viability in the region of ASM transplantation, and echocardiography, electrocardiogram, and angiography tests were used to assess cardiac function 2 months after ASM transplantation. The results from these preclinical studies were used as a foundation for application of these concepts to a human clinical trial. Here we review the results from our preclinical experiments and surgical delivery clinical trial, and describe the recent clinical studies undertaken to assess the safety and feasibility of catheter-based ASM transplantation into human subjects.","PeriodicalId":51263,"journal":{"name":"Nature Clinical Practice. Cardiovascular Medicine","volume":"3 Suppl 1 ","pages":"S42-5"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/ncpcardio0399","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25875492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI. 心肌梗死后心肌内CD34+细胞与VEGF2基因联合治疗的协同效应。

Nature Clinical Practice. Cardiovascular Medicine Pub Date : 2006-03-01 DOI: 10.1038/ncpcardio0430

Satoshi Shintani, Kengo Kusano, Masaaki Ii, Atsushi Iwakura, Lindsay Heyd, Cynthia Curry, Andrea Wecker, Mary Gavin, Hong Ma, Marianne Kearney, Marcy Silver, Tina Thorne, Toyoaki Murohara, Douglas W Losordo

{"title":"Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI.","authors":"Satoshi Shintani, Kengo Kusano, Masaaki Ii, Atsushi Iwakura, Lindsay Heyd, Cynthia Curry, Andrea Wecker, Mary Gavin, Hong Ma, Marianne Kearney, Marcy Silver, Tina Thorne, Toyoaki Murohara, Douglas W Losordo","doi":"10.1038/ncpcardio0430","DOIUrl":"https://doi.org/10.1038/ncpcardio0430","url":null,"abstract":"Previous studies have shown that local angiogenic gene therapy acts, in part, by recruiting endothelial progenitor cells (EPCs) to ischemic tissue. Recent data indicate that patients with the most severe vascular disease may have insufficient or deficient EPCs and the poorest response to angiogenic therapy. Accordingly, we hypothesized that combining human CD34(+) cell implantation with local vascular endothelial growth factor 2 (phVEGF2) gene therapy might overcome these deficiencies. The addition of VEGF2 to EPC cultures resulted in significant and dose-dependent decreases in EPC apoptosis. Phosphorylated Akt (p-Akt) was increased in VEGF2-treated EPCs. In vivo, myocardial infarction (MI) was induced by ligation of the left anterior descending coronary artery in 34 immunodeficient rats. The animals were then randomized to one of four treatment groups: cell therapy alone with human CD34(+) cells; VEGF2 gene therapy alone; combination therapy with CD34(+) cells plus phVEGF2; or CD34(-) cells and 50 microg empty plasmid. Four weeks after MI, animals treated with combination therapy showed improved fractional shortening, increased capillary density, and reduced infarct size compared with the other three groups. Combination therapy was also associated with an increased number of circulating EPCs 1 week after MI. Combined subtherapeutic doses of cell and gene therapy result in a significant therapeutic effect compared to monotherapy. This approach may overcome therapeutic failures (e.g. inability of certain patients to mobilize sufficient EPCs) and may also offer safety advantages by allowing lower dosing strategies.","PeriodicalId":51263,"journal":{"name":"Nature Clinical Practice. Cardiovascular Medicine","volume":"3 Suppl 1 ","pages":"S123-8"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/ncpcardio0430","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25875560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 68

The future of regenerative therapy in patients with chronic heart failure. 慢性心力衰竭患者再生治疗的未来。

Nature Clinical Practice. Cardiovascular Medicine Pub Date : 2006-03-01 DOI: 10.1038/ncpcardio0401

Magdi Yacoub, Ken Suzuki, Nadia Rosenthal

引用次数: 21

Timing of intracoronary bone-marrow-derived stem cell transplantation after ST-elevation myocardial infarction. st段抬高型心肌梗死后冠状动脉内骨髓干细胞移植时机的研究。

Nature Clinical Practice. Cardiovascular Medicine Pub Date : 2006-03-01 DOI: 10.1038/ncpcardio0417

Jozef Bartunek, William Wijns, Guy R Heyndrickx, Marc Vanderheyden

引用次数: 79

Catheter-based delivery of cells to the heart. 通过导管将细胞输送到心脏。

Nature Clinical Practice. Cardiovascular Medicine Pub Date : 2006-03-01 DOI: 10.1038/ncpcardio0446

Warren Sherman, Timothy P Martens, Juan F Viles-Gonzalez, Tomasz Siminiak

{"title":"Catheter-based delivery of cells to the heart.","authors":"Warren Sherman, Timothy P Martens, Juan F Viles-Gonzalez, Tomasz Siminiak","doi":"10.1038/ncpcardio0446","DOIUrl":"https://doi.org/10.1038/ncpcardio0446","url":null,"abstract":"Clinical trials have begun to assess the feasibility, safety, and efficacy of administering progenitor cells to the heart in order to repair or perhaps reverse the effects of myocardial ischemia and injury. In contrast to surgical-based injections, which are often coupled with coronary bypass surgery, catheter-based injections are less invasive and make it possible to evaluate cell products used as sole interventions. The two methods that have been tested in humans are injecting cells directly into the ventricular wall with catheter systems dedicated to that purpose and infusing cells into coronary arteries with standard balloon angioplasty catheters. The catheters described in this article have been shown in both animal and clinical studies to be effective in cell delivery and to be safe. They are well-designed and user-friendly devices, but require further investigation to identify means for optimizing cell retention and to address other limitations. Randomized, placebo-controlled trials utilizing catheters for cell implantation are under way, and others are soon to follow. The results of these studies will help to shape the direction of future investigations, both clinical and basic. The spectrum of cardiac diseases, the variety of catheters for cell delivery, and the wide array of progenitor cell types open up this young field to creative discoveries.","PeriodicalId":51263,"journal":{"name":"Nature Clinical Practice. Cardiovascular Medicine","volume":"3 Suppl 1 ","pages":"S57-64"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/ncpcardio0446","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25875412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 116

Methods of stem cell delivery in cardiac diseases. 心脏疾病的干细胞递送方法。

Nature Clinical Practice. Cardiovascular Medicine Pub Date : 2006-03-01 DOI: 10.1038/ncpcardio0447

Emerson C Perin, Javier López

引用次数: 101

Derivation of a cardiopoietic population from human mesenchymal stem cells yields cardiac progeny. 从人间充质干细胞衍生的心脏生成群体产生心脏后代。

Nature Clinical Practice. Cardiovascular Medicine Pub Date : 2006-03-01 DOI: 10.1038/ncpcardio0429

Atta Behfar, Andre Terzic

{"title":"Derivation of a cardiopoietic population from human mesenchymal stem cells yields cardiac progeny.","authors":"Atta Behfar, Andre Terzic","doi":"10.1038/ncpcardio0429","DOIUrl":"https://doi.org/10.1038/ncpcardio0429","url":null,"abstract":"Stem cells have emerged as a next-generation therapy for cardiovascular disease. Initial clinical trials in patients with myocardial infarction document improved cardiac performance after administration of stem cells, translating their regenerative potential from the bench to the bedside. However, the promise of stem cell-based therapy has yet to be fully exploited, in part due to varying degrees of efficacy on follow-up. Contributing to the uncertain outcome is the variable cardiogenic potential of patient-derived stem cells. A strategy mimicking cardiogenic signaling was here formulated to transform mesenchymal stem cells, derived from human bone marrow, into cardiac progenitors. We identified a set of recombinant trophic factors capable of collectively inducing nuclear translocation of cardiac-specific transcription factors, engaging mesenchymal stem cells into cardiopoiesis, and ultimately securing a phenotype with functional excitation-contraction coupling. Maximizing the cardiogenic potential of human mesenchymal stem cells achieves a critical step in optimizing therapeutic translation.","PeriodicalId":51263,"journal":{"name":"Nature Clinical Practice. Cardiovascular Medicine","volume":"3 Suppl 1 ","pages":"S78-82"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/ncpcardio0429","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25875416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 82

The utility of magnetic resonance imaging in cardiac tissue regeneration trials. 磁共振成像在心脏组织再生试验中的应用。

Nature Clinical Practice. Cardiovascular Medicine Pub Date : 2006-03-01 DOI: 10.1038/ncpcardio0418

Valentin Fuster, Javier Sanz, Juan F Viles-Gonzalez, Sanjay Rajagopalan

{"title":"The utility of magnetic resonance imaging in cardiac tissue regeneration trials.","authors":"Valentin Fuster, Javier Sanz, Juan F Viles-Gonzalez, Sanjay Rajagopalan","doi":"10.1038/ncpcardio0418","DOIUrl":"https://doi.org/10.1038/ncpcardio0418","url":null,"abstract":"The past decade has seen the emergence of paradigm shifts in concepts involving cardiovascular tissue regeneration, including the idea that adult stem cells originate in hematopoietic or bone marrow cells, the belief that even adult organs, such as the heart and nervous system, are capable of post-mitotic regeneration, and the concept of inherent plasticity in cells that have undergone limited lineage differentiation. There has consequently been a flurry of proposed regenerative strategies, and safety and limited efficacy data from both animal and limited human trials have been presented. The drive to push these advances from the bench to the bedside has created a unique environment where the therapeutic agents, delivery approaches, and methods of measuring efficacy (often imaging technology) are evolving practically in parallel. The encouraging results of recent cell-therapy trials should therefore be assessed cautiously and in consonance with an understanding of the advantages and limitations of delivery strategies and end points. Arguably, the use of imaging technologies to evaluate surrogate end points might help overcome the difficulty posed by large sample sizes required for hard end point trials in cardiovascular therapeutics. Cardiac magnetic resonance imaging is one of the most sensitive techniques available to assess spatial and temporal changes following local or systemic therapies, and the availability of a bevy of complementary techniques enables interrogation of physiology, morphology, and metabolism in one setting. We contend that cardiac magnetic resonance imaging is ideally suited to assess response to myocardial regeneration therapy and can be exploited to yield valuable insights into the mechanism of action of myocardial regeneration therapies.","PeriodicalId":51263,"journal":{"name":"Nature Clinical Practice. Cardiovascular Medicine","volume":"3 Suppl 1 ","pages":"S2-7"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/ncpcardio0418","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25875487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 31